+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Transarterial Chemoembolization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294511
The transarterial chemoembolization market size was valued at USD 1.43 billion in 2026 and is estimated to grow from USD 1.5 billion in 2027 to reach USD 1.97 billion by 2032, at a CAGR of 5.60% during the forecast period (2027-2032). This report is Segmented by Procedure Type (Conventional TACE, DEB-TACE), Product Type (Chemotherapeutic Agents, Drug-Eluting Particles, and More), Indication (Hepatocellular Carcinoma, and More), End-User (Hospitals, Cancer Research Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Transarterial Chemoembolization Market Trends and Insights

Rising Hepatocellular Carcinoma Incidence

Liver cancer incidence provides the demand base for the transarterial chemoembolization market. GLOBOCAN recorded 843,045 new liver and intrahepatic bile duct cancer cases in 2024, and the disease ranked third in cancer mortality with 732,489 deaths. Hepatocellular carcinoma represents 75% to 85% of these cases, linking the burden directly to TACE procedure demand. Chronic HBV and HCV infection remain important precursors, while low treatment coverage leaves many patients at continued risk. Global liver cancer incidence could reach 1.52 million new cases annually by 2050 if current viral hepatitis control trends continue. MASLD is also widening the future patient pool in North America and Western Europe beyond the historical hepatitis B population.

Shift Toward Minimally Invasive and Locoregional Therapy

Resection and transplantation are curative options for fewer than 20% of patients at diagnosis, leaving many intermediate-stage cases dependent on locoregional treatment. TACE is established in BCLC and AASLD treatment pathways for BCLC-B unresectable hepatocellular carcinoma. This supports the transarterial chemoembolization market because catheter-based care can serve patients who are not eligible for surgery. The movement toward outpatient oncology care also favors procedures that avoid inpatient surgical admissions. The 2026 Medicare Physician Fee Schedule created a net 2% increase for interventional radiology and a 7% increase in non-facility settings. This reimbursement mechanics support outpatient volume while increasing the difference in access between facility-based and community providers.

Procedure-Related Complications and Liver Decompensation

Post-procedure liver dysfunction limits repeat treatment and remains a central restraint on the transarterial chemoembolization market. A retrospective study of 549 patients found liver function impairment in 61.9% of patients after TACE and post-embolization syndrome in 27.0%. The study identified Child-Pugh class, neutrophil count, and baseline ECOG score as independent predictors of hepatic dysfunction. More severe decompensation can include ascites, encephalopathy, coagulopathy, and variceal bleeding. Patients with cirrhosis and limited hepatic reserve are especially exposed to this risk. Different monitoring intervals and escalation thresholds across treatment centers can also create uneven treatment decisions and lower procedure volumes at more cautious institutions.

Other drivers and restraints analyzed in the detailed report include:

  1. Drug-Eluting Bead and Image-Guided Technology Adoption
  2. TACE and Immunotherapy Combination Regimen Adoption
  3. High Equipment, Procedure, and Training Costs

Segment Analysis

Conventional TACE held 53.32% of the transarterial chemoembolization market share in 2026. Its position rests on extensive clinical experience, practitioner familiarity, and compatibility with cisplatin, doxorubicin, and epirubicin regimens. Conventional TACE is projected to grow at a 6.22% CAGR from 2027 to 2032 because emerging liver cancer programs can adopt lipiodol-based methods before investing in DEB-TACE platforms. Guerbet Lipiodol supply chains and flexible drug selection support use in European and Asian health systems with generic chemotherapy formularies.

DEB-TACE is gaining use in centers with dedicated microsphere platforms, including Boston Scientific’s LC Bead LUMI and Merit Medical’s HepaSphere. Conventional TACE was used in 59.3% of patients in the combination arm, while DEB-TACE was used in 40.7%. The result indicates that TACE’s immune-priming role is not limited to one procedure type. DEB-TACE offers local drug-delivery and imaging-related benefits that influence purchasing decisions.

Chemotherapeutic agents accounted for 43.35% of the transarterial chemoembolization market share in 2026. The category includes doxorubicin, cisplatin, mitomycin C, and epirubicin delivered in lipiodol emulsions or through intra-arterial infusion. Its scale reflects the continued global importance of conventional TACE and generic chemotherapy availability in emerging markets. Radiotherapeutic and adjacent intra-arterial agents serve patients whose liver reserve or contraindications limit conventional drug delivery.

Drug-eluting particles are expected to be the fastest-growing product type, with a 6.71% CAGR forecasted through 2032. Boston Scientific, Merit Medical, and Terumo hold important positions, while ABK Biomedical completed ROUTE90 phase 3 pivotal-study enrollment for Eye90 in February 2026. ABK Biomedical and COR Development announced commercial manufacturing in Ashland, Missouri, in April 2026, showing the movement of imaging-enabled embolics toward commercial supply.

Complete Report Scope:

  • By Procedure Type
    • Conventional TACE
    • DEB-TACE
  • By Product Type
    • Chemotherapeutic Agents
    • Radiotherapeutic Agents and Adjacent Intra-Arterial Agents
    • Drug-Eluting Particles
    • Non-Drug-Loaded Embolic Agents
  • By Indication
    • Hepatocellular Carcinoma
    • Metastatic Liver Cancer
    • Intrahepatic Cholangiocarcinoma
    • Other Indications
  • By End-User
    • Hospitals
    • Cancer Research Centers
    • Ambulatory Surgical Centers
    • Other End-Users
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 47.26% of the transarterial chemoembolization market share in 2026. Medicare and commercial reimbursement, dense interventional radiology networks, and specialized liver tumor boards support this position. The 2026 Medicare fee schedule increased interventional radiology payment by 2% overall and by 7% in non-facility settings. The United States leads regional procedure volume, Canada adds demand through provincial cancer care networks, and Mexico is growing as tertiary infrastructure expands.

Asia-Pacific is projected to grow at an 8.12% CAGR from 2027 to 2032, the highest regional rate in the transarterial chemoembolization market. The region has the largest absolute HCC burden and is expanding interventional oncology capacity. China’s 2025 combination approval has encouraged investment in more precise TACE delivery. Japan maintains high volumes through universal health coverage and favorable reimbursement, although Y-90 reimbursement has increased radioembolization competition.

Europe follows North America, with Germany, the United Kingdom, France, Italy, and Spain as core markets. The transarterial chemoembolization market in the Middle East and Africa has varied conditions. Saudi Arabia, the UAE, and Qatar combine high healthcare spending, available interventional infrastructure, and expanding cancer center capacity. South Africa and much of sub-Saharan Africa face equipment and specialist shortages despite unmet need linked to HBV-related disease and aflatoxin B1 exposure. Brazil and Argentina are expanding training and professional registries, while Brazil’s SUS system provides partial reimbursement for locoregional liver cancer procedures.



List of Companies Covered in this Report:

  1. ABK Biomedical Inc.
  2. Bayer
  3. Boston Scientific
  4. Cook Group
  5. Delcath Systems, Inc.
  6. Roche
  7. Guerbet
  8. Hikma Pharmaceuticals
  9. Jiangsu Hengrui Medicine Co., Ltd.
  10. Johnson & Johnson
  11. Medtronic
  12. Merck
  13. Merit Medical Systems
  14. Nippon Kayaku Co., Ltd.
  15. Novartis
  16. Pfizer
  17. Siemens Healthineers
  18. Sirtex Medical Limited
  19. Stryker
  20. Terumo

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Hepatocellular Carcinoma Incidence
4.2.2 Shift Toward Minimally Invasive and Locoregional Therapy
4.2.3 Drug-Eluting Bead and Image-Guided Technology Adoption
4.2.4 Expansion of Interventional Oncology Capacity and Reimbursement
4.2.5 TACE and Immunotherapy Combination Regimen Adoption
4.2.6 Predictive Imaging and Retreatment Optimization
4.3 Market Restraints
4.3.1 Procedure-Related Complications and Liver Decompensation
4.3.2 High Equipment, Procedure, and Training Costs
4.3.3 TACE-Refractory Disease and Stage Migration to Systemic Therapy
4.3.4 Inconsistent Bead, Drug-Loading, and Treatment Protocols
4.4 Supply Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Procedure Type
5.1.1 Conventional TACE
5.1.2 DEB-TACE
5.2 By Product Type
5.2.1 Chemotherapeutic Agents
5.2.2 Radiotherapeutic Agents and Adjacent Intra-Arterial Agents
5.2.3 Drug-Eluting Particles
5.2.4 Non-Drug-Loaded Embolic Agents
5.3 By Indication
5.3.1 Hepatocellular Carcinoma
5.3.2 Metastatic Liver Cancer
5.3.3 Intrahepatic Cholangiocarcinoma
5.3.4 Other Indications
5.4 By End-User
5.4.1 Hospitals
5.4.2 Cancer Research Centers
5.4.3 Ambulatory Surgical Centers
5.4.4 Other End-Users
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
6.3.1 ABK Biomedical Inc.
6.3.2 Bayer AG
6.3.3 Boston Scientific Corporation
6.3.4 Cook Medical
6.3.5 Delcath Systems, Inc.
6.3.6 F. Hoffmann-La Roche Ltd
6.3.7 Guerbet
6.3.8 Hikma Pharmaceuticals PLC
6.3.9 Jiangsu Hengrui Medicine Co., Ltd.
6.3.10 Johnson & Johnson
6.3.11 Medtronic plc
6.3.12 Merck & Co., Inc.
6.3.13 Merit Medical Systems, Inc.
6.3.14 Nippon Kayaku Co., Ltd.
6.3.15 Novartis AG
6.3.16 Pfizer Inc.
6.3.17 Siemens Healthineers AG
6.3.18 Sirtex Medical Limited
6.3.19 Stryker Corporation
6.3.20 Terumo Corporation
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ABK Biomedical Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Cook Medical
  • Delcath Systems, Inc.
  • F. Hoffmann-La Roche Ltd
  • Guerbet
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co., Inc.
  • Merit Medical Systems, Inc.
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation